Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression.

Bangsberg DR.

Clin Infect Dis. 2006 Oct 1;43(7):939-41. Epub 2006 Aug 23.

PMID:
16941380
2.
3.

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.

Ann Intern Med. 2007 Apr 17;146(8):564-73.

PMID:
17438315
4.

Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.

Wirden M, Delaugerre C, Marcelin AG, Ktorza N, Ait Mohand H, Dominguez S, Schneider L, Ghosn J, Pauchard M, Costagliola D, Katlama C, Calvez V.

Antimicrob Agents Chemother. 2004 Feb;48(2):644-7.

5.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
6.
7.

Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.

Tozzi V, Zaccarelli M, Narciso P, Trotta MP, Ceccherini-Silberstein F, De Longis P, D'Offizi G, Forbici F, D'Arrigo R, Boumis E, Bellagamba R, Bonfigli S, Carvelli C, Antinori A, Perno CF.

J Infect Dis. 2004 May 1;189(9):1688-95. Epub 2004 Apr 13.

PMID:
15116307
8.

Role of sequencing in therapy selection.

Keiser P.

J Acquir Immune Defic Syndr. 2002 Feb 1;29 Suppl 1:S19-27. Review.

PMID:
11832698
9.

Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa.

Barth RE, Wensing AM, Tempelman HA, Moraba R, Schuurman R, Hoepelman AI.

AIDS. 2008 Oct 18;22(16):2210-2. doi: 10.1097/QAD.0b013e328313bf87.

PMID:
18832885
11.

Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy.

Aleman S, Söderbärg K, Visco-Comandini U, Sitbon G, Sönnerborg A.

AIDS. 2002 May 3;16(7):1039-44.

PMID:
11953470
12.
13.

The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml.

Easterbrook PJ, Ives N, Waters A, Mullen J, O'Shea S, Peters B, Gazzard BG.

AIDS. 2002 Jul 26;16(11):1521-7.

PMID:
12131190
14.

Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.

Spacek LA, Shihab HM, Kamya MR, Mwesigire D, Ronald A, Mayanja H, Moore RD, Bates M, Quinn TC.

Clin Infect Dis. 2006 Jan 15;42(2):252-9. Epub 2005 Dec 12.

PMID:
16355337
15.

Levels of adherence required for virologic suppression among newer antiretroviral medications.

Kobin AB, Sheth NU.

Ann Pharmacother. 2011 Mar;45(3):372-9. doi: 10.1345/aph.1P587. Epub 2011 Mar 8. Review.

PMID:
21386024
16.

Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study.

Duwe S, Brunn M, Altmann D, Hamouda O, Schmidt B, Walter H, Pauli G, Kücherer C.

J Acquir Immune Defic Syndr. 2001 Mar 1;26(3):266-73.

PMID:
11242200
17.

Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption.

Barreiro P, de Mendoza C, González-Lahoz J, Soriano V.

Clin Infect Dis. 2005 Sep 15;41(6):897-900. Epub 2005 Aug 1.

PMID:
16107992
18.

Maintenance of naive and Th1 CD4 phenotype and lack of CD8 activation in patients switching from protease inhibitors to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimens.

Meroni L, Manganaro D, Varchetta S, Gatti N, Riva A, Monforte AD, Galli M.

J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):401-3. No abstract available.

PMID:
11707681
19.

Slow-, tight-binding HIV-1 reverse transcriptase non-nucleoside inhibitors highly active against drug-resistant mutants.

Cancio R, Mai A, Rotili D, Artico M, Sbardella G, Clotet-Codina I, Esté JA, Crespan E, Zanoli S, Hübscher U, Spadari S, Maga G.

ChemMedChem. 2007 Apr;2(4):445-8. No abstract available.

PMID:
17323401
20.

Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.

Lima VD, Gill VS, Yip B, Hogg RS, Montaner JS, Harrigan PR.

J Infect Dis. 2008 Jul 1;198(1):51-8. doi: 10.1086/588675.

PMID:
18498238

Supplemental Content

Support Center